Korro Bio (KRRO) EBIAT (2019 - 2025)
Korro Bio's EBIAT history spans 7 years, with the latest figure at -$50.0 million for Q4 2025.
- For the quarter ending Q4 2025, EBIAT fell 136.06% year-over-year to -$50.0 million, compared with a TTM value of -$117.3 million through Dec 2025, down 40.3%, and an annual FY2025 reading of -$117.3 million, down 40.3% over the prior year.
- EBIAT for Q4 2025 was -$50.0 million at Korro Bio, down from -$18.1 million in the prior quarter.
- The five-year high for EBIAT was $6.2 million in Q4 2022, with the low at -$50.0 million in Q4 2025.
- Average EBIAT over 5 years is -$21.2 million, with a median of -$21.1 million recorded in 2024.
- Year-over-year, EBIAT skyrocketed 128.77% in 2022 and then crashed 511.02% in 2023.
- Tracing KRRO's EBIAT over 5 years: stood at -$21.5 million in 2021, then skyrocketed by 128.77% to $6.2 million in 2022, then crashed by 511.02% to -$25.4 million in 2023, then increased by 16.62% to -$21.2 million in 2024, then crashed by 136.06% to -$50.0 million in 2025.
- Per Business Quant, the three most recent readings for KRRO's EBIAT are -$50.0 million (Q4 2025), -$18.1 million (Q3 2025), and -$25.8 million (Q2 2025).